In Y2014, several new agents targeted to castration resistant(recurrent)prostate cancer; CRPC, are approved in Japan.
Although such good news comes 2-3 years behind Western, it may improve the outcomes of the CRPC patients in Japan. In this issue, enzalutamide, abiraterone, and cabazitaxel are discussed by each experts from the productive industries. In addition, the experts from urological field and medical oncology field describe the role of each discipline.
Akaza H. Are you the author?
Research Center for Advanced Science and Technology (RCAST), the University of Tokyo.
Reference: Gan To Kagaku Ryoho. 2014 Jul;41(7):804.
Article in Japanese.